Abstract

Methylglyoxal (MGO) is a highly reactive metabolite of glucose. Elevated levels of MGO induce the generation of reactive oxygen species (ROS) and cause cell death in endothelial cells. Vascular endothelial cell damage by ROS has been implicated in the progression of diabetic vascular complications, cardiovascular diseases, and atherosclerosis. In this study, the protective effect of isosamidin, isolated from Peucedanum japonicum roots, on MGO-induced apoptosis was investigated using human umbilical vein endothelial cells (HUVECs). Among the 20 compounds isolated from P. japonicum, isosamidin showed the highest effectiveness in inhibiting MGO-induced apoptosis of HUVECs. Pretreatment of HUVECs with isosamidin significantly prevented the generation of ROS and cell death induced by MGO. Isosamidin prevented MGO-induced apoptosis in HUVECs by downregulating the expression of Bax and upregulating the expression of Bcl-2. MGO treatment activated mitogen-activated protein kinases (MAPKs), such as p38, c-Jun N terminal kinase (JNK), and extracellular signal-regulated kinase (ERK). In contrast, pretreatment with isosamidin strongly inhibited the activation of p38 and JNK. Furthermore, isosamidin caused the breakdown of the crosslinks of the MGO-derived advanced glycation end products (AGEs). These findings suggest that isosamidin from P. japonicum may be used as a preventive agent against MGO-mediated endothelial dysfunction in diabetes. However, further study of the therapeutic potential of isosamidin on endothelial dysfunction needs to explored in vivo models.

Highlights

  • Hyperglycemic conditions, persisting over long periods of time, can lead to the formation of advanced glycation end products (AGEs)

  • We aimed to examine the anti-glycation and cytoprotective effects of the coumarins obtained from P. japonicum in human umbilical vein endothelial cells (HUVECs) and elucidate the mechanism underlying their protective effects against MGO-induced glucotoxicity

  • We investigated the effects of isosamidin on the viability of the HUVECs using the MTT assay

Read more

Summary

Introduction

Hyperglycemic conditions, persisting over long periods of time, can lead to the formation of advanced glycation end products (AGEs). AGEs are formed endogenously by non-enzymatic glycation between the reducing sugars and the free amine groups of proteins. Increased concentrations of AGEs are well-recognized as mediators of diabetic complications, such as cataract generation, retinopathy, atherosclerosis, and nephropathy [1,2,3]. The production of pro-inflammatory mediators is increased by the interaction between the AGEs and their receptors (RAGE); this in turn, triggers the generation of reactive oxygen species (ROS) [5,6,7]. Mitogen-activated protein kinases (MAPKs), such as c-Jun N terminal kinase (JNK), extracellular signal-regulated kinase (ERK), and p38, have been reported to be activated by AGEs [8]

Objectives
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call